---
title: "Retatrutide and obstructive sleep apnea: phase 3 trials show AHI improvements"
id: "medical-news-today-0-experimental-weight-loss-drug-retatrutide-may-help-improve-sleep-apnea"
canonical_url: "https://medichelpline.com/clinical-feed/medical-news-today-0-experimental-weight-loss-drug-retatrutide-may-help-improve-sleep-apnea"
content_type: "clinical_feed_article"
specialty: "Pulmonology"
source_name: "Medical News Today"
source_url: "https://www.medicalnewstoday.com/articles/experimental-weight-loss-drug-retatrutide-may-help-improve-sleep-apnea/"
published_at: "2026-10-30T20:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Retatrutide and obstructive sleep apnea: phase 3 trials show AHI improvements
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medical-news-today-0-experimental-weight-loss-drug-retatrutide-may-help-improve-sleep-apnea
- **Specialty:** [Pulmonology](https://medichelpline.com/clinical-feed/pulmonology.md)
- **Primary Source:** Medical News Today
- **Source URL:** [Original Journal Publication](https://www.medicalnewstoday.com/articles/experimental-weight-loss-drug-retatrutide-may-help-improve-sleep-apnea/)
- **Published At:** 2026-10-30T20:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators reported results from two phase 3 trials (TRIUMPH-1-OSA and TRIUMPH-2-OSA) testing **retatrutide** in adults with overweight or obesity and moderate-to-severe **obstructive sleep apnea**. - The trials enrolled participants with and without **type 2 diabetes**; the study team randomized patients to placebo or weekly injections of 4 mg, 9 mg, or 12 mg retatrutide. - Researchers used overnight polysomnography at baseline, 24 weeks, and 80 weeks to measure changes in the **apnea–hypopnea index (AHI)** as the core objective endpoint. - By week 24 all doses produced improvements; by week 80 AHI reductions versus placebo were dose-associated in people without diabetes (reductions of 23, 34, and 32 events/hour for 4, 9, 12 mg respectively; placebo reduced AHI by just under 10 events/hour). - In the diabetes cohort reductions were similar: 20, 25, and 26 fewer events/hour for 4, 9, 12 mg versus about 10 fewer on placebo. - The authors noted that the improvements are likely attributable to weight loss rather than a direct respiratory effect of the drug; the source did not report any independent mechanism for breathing control. - Clinical interpretation will depend on additional studies, cost and access, and whether benefits persist and occur independently of weight loss; **retatrutide** is not yet FDA-approved according to the source. - The source included expert commentary from the trial lead and an external bariatric surgeon, both urging caution and calling for further evidence before replacing established therapies such as **CPAP**. - The article did not provide safety, adverse event rates, or detailed demographic breakdowns beyond diabetes status and BMI >27; it also did not report long-term comparative effectiveness versus CPAP or other AHI-modifying strategies.
## Clinical Analysis & Structured Key Points
[Skip to main content](https://www.medicalnewstoday.com/articles/experimental-weight-loss-drug-retatrutide-may-help-improve-sleep-apnea#main) [Medical News Today](https://www.medicalnewstoday.com/) * Health Conditions Health Conditions * [Alzheimer's & Dementia](https://www.medicalnewstoday.com/alzheimers-and-dementia) * [Anxiety](https://www.medicalnewstoday.com/anxiety) * [Asthma & Allergies](https://www.medicalnewstoday.com/asthma-and-allergies) * [Atopic Dermatitis](https://www.medicalnewstoday.com/program/investigating-atopic-dermatitis) * [Breast Cancer](https://www.medicalnewstoday.com/breast-cancer) * [Cancer](https://www.medicalnewstoday.com/cancer) * [Cardiovascular Health](https://www.medicalnewstoday.com/cardiovascular-health) * [COVID-19](https://www.medicalnewstoday.com/coronavirus?correlationId=2b137d5a-dcfb-464e-9ea6-72c5a54b4e92) * [Diabetes](https://www.medicalnewstoday.com/diabetes) * [Endometriosis](https://www.medicalnewstoday.com/endometriosis) * [Environment & Sustainability](https://www.medicalnewstoday.com/environment-and-sustainability) * [Exercise & Fitness](https://www.medicalnewstoday.com/exercise-and-fitness) * [Eye Health](https://www.medicalnewstoday.com/eye-health) * [Headache & Migraine](https://www.medicalnewstoday.com/headache-and-migraine) * [Health Equity](https://www.medicalnewstoday.com/health-equity) * [HIV & AIDS](https://www.medicalnewstoday.com/hiv-and-aids) * [Human Biology](https://www.medicalnewstoday.com/human-biology) * [Leukemia](https://www.medicalnewstoday.com/leukemia) * [LGBTQIA+](https://www.medicalnewstoday.com/LGBTQIA) * [Men's Health](https://www.medicalnewstoday.com/mens-health) * [Mental Health](https://www.medicalnewstoday.com/mental-health) * [Multiple Sclerosis (MS)](https://www.medicalnewstoday.com/multiple-sclerosis) * [Nutrition](https://www.medicalnewstoday.com/nutrition) * [Parkinson's Disease](https://www.medicalnewstoday.com/parkinsons-disease) * [Psoriasis](https://www.medicalnewstoday.com/psoriasis) * [Sexual Health](https://www.medicalnewstoday.com/sexual-health) * [Ulcerative Colitis](https://www.medicalnewstoday.com/program/investigating-ulcerative-colitis) * [Women's Health](https://www.medicalnewstoday.com/womens-health) * Health Products Health Products [All](https://www.medicalnewstoday.com/products-and-reviews) * [Nutrition & Fitness](https://www.medicalnewstoday.com/products-and-reviews/nutrition-and-fitness-products) * [Vitamins & Supplements](https://www.medicalnewstoday.com/products-and-reviews/vitamin-and-supplement-products) * [CBD](https://www.medicalnewstoday.com/products-and-reviews/cbd-products) * [Sleep](https://www.medicalnewstoday.com/products-and-reviews/sleep-products) * [Mental Health](https://www.medicalnewstoday.com/products-and-reviews/mental-health-services-and-products) * [At-Home Testing](https://www.medicalnewstoday.com/products-and-reviews/at-home-testing-products) * [Men’s Health](https://www.medicalnewstoday.com/products-and-reviews/mens-health-products) * [Women’s Health](https://www.medicalnewstoday.com/products-and-reviews/womens-health-products) * Discover News * [Latest News](https://www.medicalnewstoday.com/news) * [Medicare 2026 Costs](https://www.medicalnewstoday.com/articles/medicare-costs-3-key-changes-in-2026) Original Series * [Medical Myths](https://www.medicalnewstoday.com/content-series/medical-myths) * [Honest Nutrition](https://www.medicalnewstoday.com/content-series/honest-nutrition) * [Through My Eyes](https://www.medicalnewstoday.com/content-series/through-my-eyes) * [New Normal Health](https://www.medicalnewstoday.com/content-series/new-normal-health) Podcasts [All](https://www.medicalnewstoday.com/articles/in-conversation-podcast) * [ADHD in women: Breaking the stereotypes](https://www.medicalnewstoday.com/articles/adhd-women-breaking-stereotypes-masking-attention-disorder) * [Is sleep the missing piece in mental health?](https://www.medicalnewstoday.com/articles/is-sleep-the-missing-piece-in-mental-health) * [Artificial sweeteners and brain aging: What we know so far](https://www.medicalnewstoday.com/articles/artificial-sweeteners-and-brain-aging-what-we-know-so-far) * [Does the Mediterranean diet hold the key to longevity?](https://www.medicalnewstoday.com/articles/does-the-mediterranean-diet-hold-the-key-to-longevity) * [AMA: Registered dietitian answers 5 key questions about fiber and weight loss](https://www.medicalnewstoday.com/articles/can-fiber-help-lose-weight-dietitian-answers-5-key-questions) * [Health misinformation and disinformation: How to avoid it](https://www.medicalnewstoday.com/articles/health-misinformation-and-disinformation-how-to-avoid-it) * Tools General Health * [Drugs A-Z](https://www.medicalnewstoday.com/drugs) * [Health Hubs](https://www.medicalnewstoday.com/articles/content-hubs) * [Newsletter](https://www.medicalnewstoday.com/newsletter) * [Medicare Plans by State](https://www.medicalnewstoday.com/about/health-medicare-state-coverage) Health Tools * [Find a Doctor](https://connect.medicalnewstoday.com/) * [BMI Calculators and Charts](https://www.medicalnewstoday.com/articles/323586) * [Blood Pressure Chart: Ranges and Guide](https://www.medicalnewstoday.com/articles/327077) * [Breast Cancer: Self-Examination Guide](https://www.medicalnewstoday.com/articles/316898) * [Sleep Calculator](https://www.medicalnewstoday.com/articles/sleep-calculator) Quizzes * [RA Myths vs Facts](https://www.medicalnewstoday.com/articles/science-fact-or-fiction-separating-ra-myths-from-facts#1) * [Type 2 Diabetes: Managing Blood Sugar](https://www.medicalnewstoday.com/articles/managing-blood-sugar-type-2-diabetes-quiz#1) * [Ankylosing Spondylitis Pain: Fact or Fiction](https://www.medicalnewstoday.com/articles/complementary-therapies-for-as-quiz#1) * Connect About Medical News Today * [Who We Are](https://www.medicalnewstoday.com/about) * [Our Editorial Process](https://www.medicalnewstoday.com/articles/process) * [Content Integrity](https://www.medicalnewstoday.com/about/content-integrity) * [Conscious Language](https://www.medicalnewstoday.com/about/conscious-language) Find Community * [Bezzy Breast Cancer](https://www.bezzybc.com/lp/2/?verzenio&utm_source=mnt&utm_medium=nav-bar-connect) * [Bezzy MS](https://www.bezzyms.com/?utm_source=mnt&utm_medium=nav-bar-connect) * [Bezzy Migraine](https://www.bezzymigraine.com/?utm_source=mnt&utm_medium=nav-bar-connect) * [Bezzy Psoriasis](https://www.bezzypsoriasis.com/?utm_source=mnt&utm_medium=nav-bar-connect) Follow Us [](https://www.facebook.com/MedicalNewsToday/)[](https://x.com/mnt)[](https://www.instagram.com/medicalnewstoday/)[](https://www.linkedin.com/company/mednewstoday/?originalSubdomain=ec)[](https://flipboard.com/@MedNewsToday) Subscribe # Experimental weight-loss drug retatrutide may help improve sleep apnea ![](https://i0.wp.com/post.medicalnewstoday.com/wp-content/uploads/sites/3/2021/07/Katharine-Lang-500x500-Bio.png?w=105&h=105) Written by Katharine Lang on October 30, 2026 — Fact checked by Jennifer Chesak, MSJ 20 tips to lose weight safely * **Obstructive sleep apnea is a common disorder that causes people’s breathing to pause frequently during sleep.** * **The condition leads to reduced oxygen levels, daytime sleepiness, and snoring, and increases the risk of more severe health problems, such as cardiovascular disease and dementia.** * **Risk factors include overweight and obesity, age over 40, a thick neck circumference, smoking and alcohol consumption.** * **Now, a study in patients with overweight or obesity has found that treatment with the latest weight-loss drug, retatrutide, greatly reduced sleep apnea symptoms.** There are no definitive figures for obstructive sleep apnea — a condition that causes people to stop breathing frequently during sleep — as it is often undiagnosed. In the United States, sleep apnea affects up to [one-third of adults](https://www.sciencedirect.com/science/article/abs/pii/S0954611125004111), according to current estimates.. As well as causing daytime sleepiness, snoring and reduced oxygen levels, [sleep apnea increases the risk](https://www.medicalnewstoday.com/articles/178633) of a number of health conditions including cardiovascular disease, type 2 diabetes, and dementia. One of the main risk factors for sleep apnea is obesity, and with rising numbers of people with obesity, the prevalence of sleep apnea is likely to increase. Currently, the main treatment is a [continuous positive airway pressure (CPAP) machine](https://www.medicalnewstoday.com/articles/what-does-a-cpap-machine-do-when-you-stop-breathing) — a breathing device with a mask that is placed over the nose and mouth. But the results of two phase 3 clinical trial now suggests that weight-loss drugs could be an effective treatment for sleep apnea. **In the trials — whose finidngs appear in[The New England Journal of Medicine](https://www.nejm.org/doi/10.1056/NEJMoa2611477) — treatment with a once weekly injection of retatrutide led to significant improvements in sleep apnea symptoms, with an up to 50% of participants having only mild sleep apnea by the end of the trial.** [Ron Grunstein](https://www.woolcock.org.au/our-people/professor-ron-grunstein-am), MD, PhD, lead author of the paper and Professor of Sleep Medicine a the Woolcock Institute of Medical Research, NSW, Australia, told _Medical News Today_ : > “I think the finding is very important because there are many people with moderate to severe sleep apnea who are looking for alternative treatments to nasal CPAP and, as we emphasised in the paper retatrutide is providing an extra benefit for improving metabolic syndrome or metabolic dysfunction, which CPAP does not provide. The weight loss was substantial in the study and generally the reaction has been very positive.” [Mir Ali](https://www.memorialcare.org/providers/mir-b-ali), MD, bariatric surgeon, a bariatric medicine specialist and medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA, who was not involved in this research, also commented on its findings. “Obstructive sleep apnea (OSA) improving with weight loss is a well-established finding in morbidly obese patients, regardless of how the weight loss is achieved. In fact, OSA is often one of the first conditions to improve following surgical weight loss,” Ali told _MNT_. ## Retatrutide tested in people with and without diabetes Retatrutide is the latest in a group of medications that work on hormone receptors to control appetite and metabolism. It follows [semaglutide](https://www.medicalnewstoday.com/articles/drugs-ozempic) (Ozempic/Wegovy), a glucagon-like peptide-1 (GLP-1) agonist, and [tirzepatide](https://www.medicalnewstoday.com/articles/drugs-mounjaro) (Mounjaro/Zepbound), which works on both GLP-1 receptors and glucose-dependent insulinotropic polypeptide (GIP) receptors. **In addition to working on both GLP-1 and GIP receptors, retatrutide also activates glucagon receptors, so is called a triple hormone receptor agonist. It is not yet licensed by the Food and Drug Administration (FDA) or any other authorities as it is still in phase 3 trials.** To investigate retatrutide’s effect on sleep apnea, researchers launched 2 trials — TRIUMPH-1-OSA in 243 people without type 2 diabetes and TRIUMPH-2-OSA in 448 people with type 2 diabetes. All participants had overweight or obesity (body mass index greater than 27) and moderate to severe sleep apnea, with at least 15 breathing pauses per hour when sleeping. For both the double-blind, randomized, placebo-controlled trials, researchers divided the participants into 4 treatment groups — placebo, 4 milligrams (mg), 9 mg or 12 mg of retatrutide, by weekly injection. At the beginning of the study, at 24 weeks and at the end of the 80 week trial, participants stayed overnight in the sleep clinic for [polysomnography](https://www.medicalnewstoday.com/articles/polysomnography) to assess their sleep apnea. The researchers recorded the changes in the apnea–hypopnea index (AHI), which records the number of pauses and partial pauses in breathing per hour. ## Any dose of retatrutide led to improvements in sleep apnea symptoms By week 24, all three doses of retatrutide led to symptom improvement. By week 80, in people without diabetes, the 4 mg dose decreased AHI by 23 events per hour, 9 mg by 34 per hour, and 12 mg by 32 per hour, against a reduction of just under 10 events per hour on placebo. There were similar improvements in those with diabetes, with 4 mg leading to 20 fewer events per hour, 9 mg to 25 fewer per hour, and those on 12mg having 26 fewer apneas or hypopneas per hour, compared with 10 fewer on placebo. Grunstein explained the findings: > “The improvements in sleep apnea symptoms and the objective effects are likely to be a result of the weight loss. There is no evidence that there is an independent direct effect of retatrutide on breathing control or some cause of sleep apnea.” ## Might retatrutide become a routine treatment for sleep apnea? Grunstein emphasised that further studies would be needed to verify the results, and future use would depend on price and availability, but that their findings were very encouraging. And Ali cautioned: “The primary approach to treating obstructive sleep apnea is addressing the underlying condition, such as obesity. [CPAP therapy](https://www.medicalnewstoday.com/articles/what-does-a-cpap-machine-do-when-you-stop-breathing) is used for patients regardless of weight to improve sleep quality. For a medication to be considered a viable alternative to established therapies, studies would need to prove it improves OSA independently of weight loss.” “Increasingly, tirzepatide has become a treatment for sleep apnea, and retatrutide has some additional benefits,” Grunstein told _Medical News Today_. “It is the first treatment that’s been shown to improve sleep apnea in patients with type 2 diabetes. I think the big thing is the metabolic advantage with retatrutide. This study converted a lot of people from type 2 diabetes to pre-diabetes and even to not having diabetes,” concluded the study author. * [Clinical Trials / Drug Trials](https://www.medicalnewstoday.com/categories/clinical_trials) * [Obesity / Weight Loss / Fitness](https://www.medicalnewstoday.com/categories/fitness-obesity) * [Sleep / Sleep Disorders / Insomnia](https://www.medicalnewstoday.com/categories/sleep) * [Drugs](https://www.medicalnewstoday.com/categories/drugs) ### How we reviewed this article: History Share this article [](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.medicalnewstoday.com%2Farticles%2Fexperimental-weight-loss-drug-retatrutide-may-help-improve-sleep-apnea%3Futm_medium%3Dsocial%26utm_source%3Dfacebook%26utm_campaign%3Dsocial-sharebar-referred-desktop "Share on Facebook") [](https://twitter.com/intent/tweet?via=mnt&text=Sleep%20apnea%3A%20Experimental%20weight-loss%20drug%20may%20improve%20symptoms&url=https%3A%2F%2Fwww.medicalnewstoday.com%2Farticles%2Fexperimental-weight-loss-drug-retatrutide-may-help-improve-sleep-apnea%3Futm_medium%3Dsocial%26utm_source%3Dx%26utm_campaign%3Dsocial-sharebar-referred-desktop "Share on X") ![](https://i0.wp.com/post.medicalnewstoday.com/wp-content/uploads/sites/3/2021/07/Katharine-Lang-500x500-Bio.png?w=105&h=105) Written by Katharine Lang on October 30, 2026 — Fact checked by Jennifer Chesak, MSJ ## Was this article helpful? YesNo © 2026 Healthline Media UK Ltd, London, UK. All rights reserved. MNT is the registered trade mark of Healthline Media. Healthline Media is an RVO Health Company. Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a healthcare professional. [See additional information](https://www.medicalnewstoday.com/about/additional-information). * [About Us](https://www.medicalnewstoday.com/about) * [Contact Us](https://www.medicalnewstoday.com/about/contact-us) * [Terms of Use](https://www.medicalnewstoday.com/about/terms-of-use) * [Privacy Notice](https://www.medicalnewstoday.com/about/privacy-notice) * Privacy Settings * [Advertising Policy](https://www.medicalnewstoday.com/ad-policy) * [Licensing Requests](https://permissions.rvohealth.threesai.com/) * [Health Topics](https://www.medicalnewstoday.com/directory/a-b) * [Health Hubs](https://www.medicalnewstoday.com/articles/content-hubs) * [Medical Affairs](https://www.medicalnewstoday.com/about/reviewers) * [Content Integrity](https://www.medicalnewstoday.com/about/content-integrity) * [Newsletters](https://www.medicalnewstoday.com/newsletter) * [Your Privacy Choices](https://privacyportal.onetrust.com/webform/b45407c6-ee79-4a08-912e-02ce898f9a14/6a88ff3d-e0ff-44b3-bb05-e8a2a65072fe?anonymousId=bcca095b-968c-45b9-967f-5add60cc45ca&orgId=c69bb2d7-c8f5-4d6f-a080-8c2266e12003)![CCPA Privacy Options Logo](https://i0.wp.com/assets.healthline.com/content/ccpaprivacyoptions29x14.png) [](https://www.healthlinemedia.com/?utm_source=medicalnewstoday.com&utm_medium=site&utm_campaign=footer&utm_content=logo) [About](https://www.healthlinemedia.com/?utm_source=medicalnewstoday.com&utm_medium=site&utm_campaign=footer&utm_content=about)[Careers](https://rvohealth.com/careers)[Advertise with us](https://www.healthlinemedia.com/advertise?utm_source=medicalnewstoday.com&utm_medium=site&utm_campaign=footer&utm_content=advertise) OUR BRANDS [Healthline](https://www.healthline.com/)[Medical News Today](https://www.medicalnewstoday.com/)[Greatist](https://greatist.com/)[Psych Central](https://psychcentral.com/)[Bezzy](https://bezzy.com/) [![This website is certified by AACI. Click to verify.](https://media.post.rvohealth.io/wp-content/uploads/2026/03/image-1.png)](https://aacihealthcare.com/certificates/c143-2-2021-trust-usa/) ## History 1. Current version Written by Katharine Lang ![](https://www.medicalnewstoday.com/navi/reinforce?&domain=medicalnewstoday.com)
## Related Clinical Research

- [Semaglutide plus menopause hormone therapy linked to greater weight loss in midlife women](https://medichelpline.com/clinical-feed/medical-news-today-0-ozempic-plus-hormone-therapy-may-help-boost-weight-loss-at-menopause.md)
- [GLP-1 receptor agonists and PMOS: evidence, mechanisms, and who may benefit](https://medichelpline.com/clinical-feed/medical-news-today-0-can-glp-1s-really-help-treat-pmos-experts-answer-3-key-questions.md)
- [GLP-1 receptor agonist weight loss in breast cancer patients on endocrine therapy](https://medichelpline.com/clinical-feed/pubmed-42932003.md) (DOI: 10.1007/s10549-026-08096-z)
- [ENDO 2026: Progress and Resilience in Endocrinology and Obesity Care](https://medichelpline.com/clinical-feed/endocrine-news-0-endo-2026-progress-and-resilience.md)
- [GLP‑1 and Dual GIP/GLP‑1 Receptor Agonists: Psychopharmacology and Potential Neuropsychiatric Effe](https://medichelpline.com/clinical-feed/pubmed-42624955.md) (DOI: 10.1007/s11920-026-01709-w)

## Navigation
- [← Back to Pulmonology Feed](https://medichelpline.com/clinical-feed/pulmonology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.